CoChat

BCAA metabolism in pancreatic cancer affects lipid balance by regulating fatty acid import into mitochondria

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) has been associated with the host dysmetabolism of branched-chain amino acids (BCAAs), however, the implications for the role of BCAA metabolism in PDAC development or progression are not clear. The mitochondrial catabolism of valine, leucine, and isoleucine is a multistep process leading to the production of short-chain R-CoA species. They can be subsequently exported from mitochondria as short-chain carnitines (SC-CARs), utilized in anabolic pathways, or released from the cells. Methods: We examined the specificities of BCAA catabolism and cellular adaptation strategies to BCAA starvation in PDAC cells in vitro. We used metabolomics and lipidomics to quantify major metabolic changes in response to BCAA withdrawal. Using confocal microscopy and flow cytometry we quantified the fluorescence of BODIPY probe and the level of lipid droplets (LDs). We used BODIPY-conjugated palmitate to evaluate transport of fatty acids (FAs) into mitochondria. Also, we have developed a protocol for quantification of SC-CARs, BCAA-derived metabolites. Results: Using metabolic profiling, we found that BCAA starvation leads to massive triglyceride (TG) synthesis and LD accumulation. This was associated with the suppression of activated FA transport into the mitochondrial matrix. The suppression of FA import into mitochondria was rescued with the inhibitor of the acetyl-CoA carboxylase (ACC) and the activator of AMP kinase (AMPK), which both regulate carnitine palmitoyltransferase 1A (CPT1) activation status. Conclusions: Our data suggest that BCAA catabolism is required for the import of long chain carnitines (LC-CARs) into mitochondria, whereas the disruption of this link results in the redirection of activated FAs into TG synthesis and its deposition into LDs. We propose that this mechanism protects cells against mitochondrial overload with LC-CARs and it might be part of the universal reaction to amino acid perturbations during cancer growth, regulating FA handling and storage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40170-024-00335-5

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 BCAA starvation affects cell growth and mitochondrial metabolism. a Cell viability assay comparing no glucose (-Glc), no glutamine (-Gln), and no BCAA (-BCAA) conditions after 72 h of starvation. Two-way ANOVA followed by Tukey’s multiple comparisons tests. N > 4, n > 50. Criteria of significance: *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. b Respiration of intact cells measured by high-resolution respirometry using indicated cell lines and starvation conditions, including BCAA. Cells were starved of BCAAs for 48 h prior experiment. Two-way ANOVA followed by Tukey’s multiple comparisons tests. N > 3, n ≥ 6. Criteria of significance: *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. c Levels of mitochondrial metabolites measured by GC-MS expressed as a log2 fold change compared to complete medium (ctrl). Cells were starved 48 h prior the experiment. Citrate (CIT), 2-oxoglutarate (2OG), succinate (SUCC), fumarate (FUM), malate (MAL), glutamate (Glu), aspartate (Asp), and alanine (Ala)
Fig. 1 BCAA starvation affects cell growth and mitochondrial metabolism. a Cell viability assay comparing no glucose (-Glc), no glutamine (-Gln), and no BCAA (-BCAA) conditions after 72 h of starvation. Two-way ANOVA followed by Tukey’s multiple comparisons tests. N > 4, n > 50. Criteria of significance: *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. b Respiration of intact cells measured by high-resolution respirometry using indicated cell lines and starvation conditions, including BCAA. Cells were starved of BCAAs for 48 h prior experiment. Two-way ANOVA followed by Tukey’s multiple comparisons tests. N > 3, n ≥ 6. Criteria of significance: *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. c Levels of mitochondrial metabolites measured by GC-MS expressed as a log2 fold change compared to complete medium (ctrl). Cells were starved 48 h prior the experiment. Citrate (CIT), 2-oxoglutarate (2OG), succinate (SUCC), fumarate (FUM), malate (MAL), glutamate (Glu), aspartate (Asp), and alanine (Ala)CC BY · PubMed Central
Fig. 2 BCAA starvation induces metabolic remodeling. a Partial least squares discriminant analysis (PLS-DA) scores plot (left) depicting the stratification of samples based on the presence/absence of BCAAs in PC3 (t3). PLS-DA was performed in Workflow4metabolomics using TIC-normalized data. The loadings plot corresponding to PLS-DA (right) shows a negative correlation between BCAA/BCKA and TG species. b Volcano plots of -BCAA-treated cells compared to +BCAA treatment depicting several lipid and metabolic classes, i.e. BCAA/BCKA, short-chain carnitines (SC-CAR), BCAA-derived carnitines (BCAA-CAR), long-chain carnitines (LC-CAR), cholesteryl-esters (CE), diacylglycerols (DG), cholesterol, triglycerides (TG), ether-linked TG (TG-O), free fatty acids (FA), free amino acids (AA), and TCA-cycle metabolites (TCA). Cells were starved 48 h prior the experiment. P-values were calculated by Welch’s t-test using the matrixTests package in RStudio
Fig. 2 BCAA starvation induces metabolic remodeling. a Partial least squares discriminant analysis (PLS-DA) scores plot (left) depicting the stratification of samples based on the presence/absence of BCAAs in PC3 (t3). PLS-DA was performed in Workflow4metabolomics using TIC-normalized data. The loadings plot corresponding to PLS-DA (right) shows a negative correlation between BCAA/BCKA and TG species. b Volcano plots of -BCAA-treated cells compared to +BCAA treatment depicting several lipid and metabolic classes, i.e. BCAA/BCKA, short-chain carnitines (SC-CAR), BCAA-derived carnitines (BCAA-CAR), long-chain carnitines (LC-CAR), cholesteryl-esters (CE), diacylglycerols (DG), cholesterol, triglycerides (TG), ether-linked TG (TG-O), free fatty acids (FA), free amino acids (AA), and TCA-cycle metabolites (TCA). Cells were starved 48 h prior the experiment. P-values were calculated by Welch’s t-test using the matrixTests package in RStudioCC BY · PubMed Central
Fig. 3 Triglyceride synthesis and lipid droplets are upregulated in PDAC cells starved of BCAAs. a Left, imaging of neutral lipids using BODIPY™ 493/503 (green) and nuclei using Hoechst 33342 (blue) depicts build-up of lipid droplets in PaTu 8902 and MIA PaCa-2 cells. Right, the quantification of BODIPY™ 493/503 fluorescence intensity expressed as as per-cent of HOECHST 33342. N = 2. n ≥ 4. One-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons tests. b Flow cytometry of PaTu 8902 (up) and MIA PaCa-2 (down); BODIPY™ 493/503 mean fluorescence intensities calculated from 104 events. Cells were starved of BCAA for 48 h prior experiment. Color coding: black for control, green for 3-MA, orange for CQ, corn yellow for BafA, blue for -BCAA, red for BCKA, light blue for DGAT1i, pink for DGAT2i, grey for charcoal-stripped serum. One-way ANOVA followed by Tukey’s multiple comparisons tests. N > 3, n ≥ 6. Criteria of significance: *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. c Working scheme (right) depicting inhibitors used in the experiments, potentially causative in LD formation. Carnitine palmitoyltransferase 1A inhibitor (CPT1, etomoxir (ETO), 50 µM), diacylglycerol-O-acetyl-transferase 1 inhibitor (DGAT1i, A922500, 10 µM), diacylglycerol-O-acetyl-transferase 2 inhibitor (DGAT2i, PF-06424439, 20 µM), autophagy initiation inhibitor 3-methyladenine (3-MA, 1 mM), autophagy inhibitor bafilomycin A1 (BafA, 100 nM), autophagy inhibitor chloroquine (CQ, 100 µM), charcoal-stripped FBS (CHS-FBS). Created with BioRender.com
Fig. 3 Triglyceride synthesis and lipid droplets are upregulated in PDAC cells starved of BCAAs. a Left, imaging of neutral lipids using BODIPY™ 493/503 (green) and nuclei using Hoechst 33342 (blue) depicts build-up of lipid droplets in PaTu 8902 and MIA PaCa-2 cells. Right, the quantification of BODIPY™ 493/503 fluorescence intensity expressed as as per-cent of HOECHST 33342. N = 2. n ≥ 4. One-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons tests. b Flow cytometry of PaTu 8902 (up) and MIA PaCa-2 (down); BODIPY™ 493/503 mean fluorescence intensities calculated from 104 events. Cells were starved of BCAA for 48 h prior experiment. Color coding: black for control, green for 3-MA, orange for CQ, corn yellow for BafA, blue for -BCAA, red for BCKA, light blue for DGAT1i, pink for DGAT2i, grey for charcoal-stripped serum. One-way ANOVA followed by Tukey’s multiple comparisons tests. N > 3, n ≥ 6. Criteria of significance: *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. c Working scheme (right) depicting inhibitors used in the experiments, potentially causative in LD formation. Carnitine palmitoyltransferase 1A inhibitor (CPT1, etomoxir (ETO), 50 µM), diacylglycerol-O-acetyl-transferase 1 inhibitor (DGAT1i, A922500, 10 µM), diacylglycerol-O-acetyl-transferase 2 inhibitor (DGAT2i, PF-06424439, 20 µM), autophagy initiation inhibitor 3-methyladenine (3-MA, 1 mM), autophagy inhibitor bafilomycin A1 (BafA, 100 nM), autophagy inhibitor chloroquine (CQ, 100 µM), charcoal-stripped FBS (CHS-FBS). Created with BioRender.comCC BY · PubMed Central
Fig. 4 FA import into mitochondria is diverted into TG synthesis in BCAA-starved cells. a Routine or maximum respiration of intact cells (PaTu 8902) measured using high-resolution respirometry. Respiratory rates of BSA-palmitate (FA 16:0) with or without ETO addition demonstrate the difference between -BCAA and +BCAA treatment. The assay was performed in RPMI containing 1% FBS and BSA-palmitate (34 µM BSA, 200 µM palmitate). One-way ANOVA followed by Tukey’s multiple comparisons tests. N > 3, n ≥ 9. Criteria of significance: ***p < 0.001, ****p < 0.0001. b Confocal microscopy imaging using fluorescent FA conjugate (BODIPY FL C16, C16-BODIPY, green) and a mitochondrial network (Mitotracker™ Red) shows the import of fluorescently-labeled palmitate into mitochondria only with BCAA-containing treatment, which was augmented in DGAT1i-treated cells (inhibition of TG synthesis). No import of C16-BODIPY was observed under BCAA-depleted conditions. ETO treatment inhibits the import of C16-BODIPY into mitochondria and induces LD formation. c Log2 fold change of LC-CAR and FA species under designated conditions, namely -BCAA, +BCAA, ETO treatment, and DGAT1i treatment
Fig. 4 FA import into mitochondria is diverted into TG synthesis in BCAA-starved cells. a Routine or maximum respiration of intact cells (PaTu 8902) measured using high-resolution respirometry. Respiratory rates of BSA-palmitate (FA 16:0) with or without ETO addition demonstrate the difference between -BCAA and +BCAA treatment. The assay was performed in RPMI containing 1% FBS and BSA-palmitate (34 µM BSA, 200 µM palmitate). One-way ANOVA followed by Tukey’s multiple comparisons tests. N > 3, n ≥ 9. Criteria of significance: ***p < 0.001, ****p < 0.0001. b Confocal microscopy imaging using fluorescent FA conjugate (BODIPY FL C16, C16-BODIPY, green) and a mitochondrial network (Mitotracker™ Red) shows the import of fluorescently-labeled palmitate into mitochondria only with BCAA-containing treatment, which was augmented in DGAT1i-treated cells (inhibition of TG synthesis). No import of C16-BODIPY was observed under BCAA-depleted conditions. ETO treatment inhibits the import of C16-BODIPY into mitochondria and induces LD formation. c Log2 fold change of LC-CAR and FA species under designated conditions, namely -BCAA, +BCAA, ETO treatment, and DGAT1i treatmentCC BY · PubMed Central
Fig. 5 BCAA-derived carnitines respond as regulators of LC-CAR oxidation. a Log2 fold change in BCAA-CARs with -BCAA treatment quantified by LC-MS method. Paired t-test. N > 3, n ≥ 9. Criteria of significance: ***p < 0.001, ****p < 0.0001. b Rescue effect of BCAA-CARs under BCAA-depleted conditions with BCKA, free carnitine, and other compounds relevant to mitochondrial metabolism. c Confocal microscopy demonstrating the rescue effect of mitochondrial FA import with BCAA (o/n), BCKA (48 h), and free L-carnitine (1 mM, o/n) treatment
Fig. 5 BCAA-derived carnitines respond as regulators of LC-CAR oxidation. a Log2 fold change in BCAA-CARs with -BCAA treatment quantified by LC-MS method. Paired t-test. N > 3, n ≥ 9. Criteria of significance: ***p < 0.001, ****p < 0.0001. b Rescue effect of BCAA-CARs under BCAA-depleted conditions with BCKA, free carnitine, and other compounds relevant to mitochondrial metabolism. c Confocal microscopy demonstrating the rescue effect of mitochondrial FA import with BCAA (o/n), BCKA (48 h), and free L-carnitine (1 mM, o/n) treatmentCC BY · PubMed Central
Fig. 6 Inhibition of ACC rescues mitochondrial FA import and diminishes LDs. a Loss of LDs after ACCi treatment shown by confocal microscopy in MIA PaCa-2 cells. b Protein levels of AMPK, and phosphorylated AMPK (P-AMPK, Phospho-AMPKα (Thr172)). c Flow cytometry of PaTu 8902 and MIA PaCa-2 cells stained with BODIPY and treated with ACCi (10 µM, o/n), AICAR (500 µM, o/n), and compound C (10 µM, o/n) compared to controls. One-way ANOVA followed by Tukey’s multiple comparisons test. N = 3. n ≥ 5. d C16-BODIPY staining after ACCi, AICAR, and Compound C treatment demonstrated by confocal microscopy in MIA PaCa-2 cells
Fig. 6 Inhibition of ACC rescues mitochondrial FA import and diminishes LDs. a Loss of LDs after ACCi treatment shown by confocal microscopy in MIA PaCa-2 cells. b Protein levels of AMPK, and phosphorylated AMPK (P-AMPK, Phospho-AMPKα (Thr172)). c Flow cytometry of PaTu 8902 and MIA PaCa-2 cells stained with BODIPY and treated with ACCi (10 µM, o/n), AICAR (500 µM, o/n), and compound C (10 µM, o/n) compared to controls. One-way ANOVA followed by Tukey’s multiple comparisons test. N = 3. n ≥ 5. d C16-BODIPY staining after ACCi, AICAR, and Compound C treatment demonstrated by confocal microscopy in MIA PaCa-2 cellsCC BY · PubMed Central
Fig. 7 Import of FAs into mitochondria negatively affects cell viability. a Cell viability of MIA PaCa-2 cells treated 72 h with DGAT1i, DGAT2i, and ACCi in BCAA-containing or deficient medium. Values are percent of respective control with no addition of pharmacological inhibitor. One-way ANOVA followed by Tukey’s multiple comparisons test. N > 3, n > 12. Criteria of significance: ***p < 0.001, ****p < 0.0001. b Cell viability of MIA PaCa-2 treated with DGAT1i, DGAT1i + ACCi and DGAT1i + carnitine in complete medium, no glutamine, no glucose, and BCAA-depleted cells (-BCAA). Values are percent of respective control with no addition of pharmacological inhibitor. One-way ANOVA followed by Tukey’s multiple comparisons test. N > 3, n > 20. Criteria of significance: ***p < 0.001, ****p < 0.0001
Fig. 7 Import of FAs into mitochondria negatively affects cell viability. a Cell viability of MIA PaCa-2 cells treated 72 h with DGAT1i, DGAT2i, and ACCi in BCAA-containing or deficient medium. Values are percent of respective control with no addition of pharmacological inhibitor. One-way ANOVA followed by Tukey’s multiple comparisons test. N > 3, n > 12. Criteria of significance: ***p < 0.001, ****p < 0.0001. b Cell viability of MIA PaCa-2 treated with DGAT1i, DGAT1i + ACCi and DGAT1i + carnitine in complete medium, no glutamine, no glucose, and BCAA-depleted cells (-BCAA). Values are percent of respective control with no addition of pharmacological inhibitor. One-way ANOVA followed by Tukey’s multiple comparisons test. N > 3, n > 20. Criteria of significance: ***p < 0.001, ****p < 0.0001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 33

Metadata

Authors
Gotvaldová, K., Špačková, J., Novotný, J., Baslarová, K., Ježek, P., Rossmeislová, L., Gojda, J., & Smolková, K.
Affiliations
  • Czech Academy of Sciences, Institute of Physiology (CZ)
  • Charles University (CZ)
Corresponding author
Smolková, Katarína
Venue
Cancer & Metabolism
Published
2024-03-26
Volume
12
Issue
1
Pages
10-10
ISSN
2049-3002 (ISSN-L)
OpenAlex
W4393200926
Cited by
27
References
51
Citations by year
2026: 9 · 2025: 16 · 2024: 2
FWCI
5.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer & Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Agentura Pro Zdravotnický Výzkum České Republiky (NV19-01–00101)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
branched-chain amino acids, pancreatic ductal adenocarcinoma, BCAA catabolism, lipid droplets, triglyceride synthesis, acetyl-CoA carboxylase, AMP kinase, CPT1A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCAA metabolism in pancreatic cancer affects lipid balance by regulating fatty acid import into mitochondria. https://app.cochat.ai/papers/10.1186/s40170-024-00335-5
The paper
Gotvaldová, K., Špačková, J., Novotný, J., Baslarová, K., Ježek, P., Rossmeislová, L., Gojda, J., & Smolková, K. (2024). BCAA metabolism in pancreatic cancer affects lipid balance by regulating fatty acid import into mitochondria. Cancer & Metabolism. https://doi.org/10.1186/s40170-024-00335-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.